** Vaccine maker Moderna's MRNA.O shares down 4.3% at $33.71
** Brokerage Berenberg cuts PT to $30 from $33, maintains rating to "hold"
** The new PT represents 14.7% downside to stock's last close on Wednesday
** Berenberg sees multiple headwinds for MRNA which include a poor commercial outlook for its respiratory vaccines, and an unsupportive U.S. political environment
** Sanofi's SASY.PA entry into the COVID-19 market with the Novavax NVAX.O vaccine will increase pricing pressure and reduce MRNA's market share, brokerage says
** "Moderna will not meet its guidance to break even by 2028 on our forecasts," brokerage adds
** Two brokerages rate stock "buy" or higher, seven "hold" or equivalent, and one "underperform"; their median PT is $54.51, according to data compiled by LSEG
** MRNA has fallen 63.2% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。